# Clinical Trials Data EGFR - Document 72

# Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT01829178

"eligibilityCriteria": "Inclusion Criteria:\n\n\* age\\>18 years\n\* diagnosed\n\* measurable upper gastrointestinal adenocarcinoma\n\* swallow problem\n\* would like to participate in the study\n\* Glomerular filtration rate(GFR)\\>45ml/min/1.73m2\n\nExclusion Criteria:\n\n\* end stage renal disease\n\* requiring dialysis\n\* post transplantation\n\* receiving contrast media during last 72 hours\n\* chronic use of corticosteroids\n\* chronic use of angiotensin-converting enzyme inhibitor(ACEI )\n\* untreated hypo-and hyperthyroidism\n\* ejection fraction\\<60%\n\* active urinary tract infection\n\* iver disease ( five fold increase of liver enzyme in asymptomatic or 3 fold increase in symptomatic\n\* use of other nephrotoxic agents such as aminoglycoside, amphotericin\n\* karnofsky performance status \\<70",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, there is no specific mention of the patient's eligibility being affected by an EGFR gene mutation. The inclusion and exclusion criteria focus primarily on age, diagnosis (upper gastrointestinal adenocarcinoma), various health statuses and conditions (such as renal function, liver function, thyroid function), medications, and performance status. As long as the patient meets the other listed criteria for participation and does not match any exclusion criteria, having an EGFR gene mutation would not automatically make them ineligible for this particular trial. However, it's always important to consult with the research team conducting the trial for any unlisted considerations and to verify eligibility.